首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease
【24h】

Direct Coombs Test Positivity in B-Chronic Lymphoid Leukemia: a Marker of Advanced Clinical Disease

机译:直接Coombs在B-慢性淋巴白血病中试验阳性:一种晚期临床疾病的标志物

获取原文
获取外文期刊封面目录资料

摘要

Background: Chronic lymphoid leukemia (CLL) is a malignant hematopoietic disorder, the most common of all adult leukemias with a distinctive immunophenotype. It is well established that CLL patients can have autoimmune complications, amongst them autoimmune hemolytic anemia as the most frequent. This study was carried out to determine the frequency of direct Coombs Test positivity in CLL patients and its possible correlation with Rai staging, hematological parameters and biochemical markers. Materials and Methods: This descriptive cross sectional study was carried at Liaquat National Hospital from January 2011 to June 2013. Sixty untreated patients with B- chronic lymphoid leukemia were enrolled. Complete blood count, direct Coombs test, serum urea, creatinine, uric acid and LDH levels were determined. Data were compiled and analyzed using SPSS version 21. Results: Out of 60 patients, 42(70%) were males and 18(30%) were females. Mean age was . Male to female ratio was 2.1: 1. The frequency of direct antiglobulin test (DAT) positivity was found to be 23.3%. The monospecific IgG was positive in 11 patients (18.3%); C3d positivity was evident in 1 patient (1.6%) and 2 patients (3.3%) had dual IgG and C3d positivity. The mean hemoglobin was . Significantly low mean hemoglobin of was seen in Coombs positive patients compared with negative patients having a mean hemoglobin level of (P0.001). DAT positivity also demonstrated a positive association with advanced Rai stage III disease (P0.01). No associations were noted with age, gender and biochemical markers. Conclusions: Direct Coombs test positivity in CLL in our patients, unlike in Western studies, appears relatively high, indicating significant autoimmune hemolytic anemia and advanced Rai stage in our setting. DAT positivity can be considered as a surrogative marker for advanced clinical disease.
机译:背景:慢性淋巴白血病(CLL)是恶性造血障碍,最常见的是所有成年白血病,具有独特的免疫蛋白型。很好地确定,CLL患者可以具有自身免疫并发症,其中包括自身免疫性溶血性贫血,作为最常见的。该研究进行了确定CLL患者直接Coombs测试阳性的频率及其与RAI分期,血液学参数和生化标志物的相关性。材料和方法:这项描述性横截面研究于2011年1月至2013年6月举办李亚达国家医院。注册了60例患有B-慢性淋巴白血病的六十次未处理的患者。确定完全血统,直接组织试验,血清尿素,肌酐,尿酸和LDH水平。使用SPSS版本21编译和分析数据。结果:超过60名患者,42名(70%)是男性,18名(30%)是女性。平均年龄是。男性与女性比例为2.1:1。发现直接抗气素试验(DAT)阳性的频率为23.3%。单特异性IgG在11名患者中阳性(18.3%);在1名患者(1.6%)和2名患者(3.3%)中,C3D阳性明显具有双IgG和C3D阳性。平均血红蛋白是。在Coombs阳性患者中观察到显着低平均平均血红蛋白,而具有平均血红蛋白水平的阴性患者(P <0.001)。 DAT阳性还证明了与先进的RAI阶段III疾病阳性相关(P <0.01)。年龄,性别和生化标记没有注意到任何关联。结论:直接COMBS在我们患者中的CLL中的阳性,与西方研究不同,看起来比较高,表明我们的环境中显着的自身免疫溶血性贫血和先进的RAI阶段。 DAT阳性可以被认为是针对晚期临床疾病的代理标志物。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号